AVITA Medical highlighted data from the British Burn Association Annual Meeting showing that RECELL, its spray-on skin cell technology, reduced hospital stays for burn patients. This real-world analysis, the largest of its kind for skin cell suspension autograft, demonstrated significant cost savings and improved patient outcomes. The study reinforces RECELL’s clinical and economic value in treating burns.
This news is important because it validates the real-world effectiveness of RECELL in a large patient population, solidifying its position as a valuable treatment option for burns. Shorter hospital stays translate to reduced healthcare costs, a crucial factor for both healthcare providers and payers. The data strengthens the argument for wider adoption of RECELL in burn centers, potentially improving the standard of care for burn patients.
A retrospective study of over 6,300 patients treated with RECELL between 2019 and 2024 found a significant reduction in hospital stays. For patients with burns covering less than 30% of their body surface area treated with RECELL alone, the length of stay decreased by 6.2 days (35.7%) compared to traditional skin grafts. This resulted in approximately $300 million in cost savings over the five-year study period. RECELL is currently used in over 130 burn centers across the United States.
This positive data reinforces the potential for RECELL to become a standard of care in burn treatment. Increased adoption could lead to significant cost savings for healthcare systems and improved outcomes for patients, including faster healing, reduced pain, and fewer procedures. This also positions AVITA Medical for continued growth and market leadership in the acute wound care space.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
